January 20, 2005 -- The end-of-the-day blues triumphed once again on Thursday, as biotech gave up early gains and finished lower. The Centient Biotech 200 lost 23.21 points to 3340.18, a .69% slide. That put biotech equal with the NYSE Composite, which also dropped .69%, but at a lower loss than the Nasdaq, which declined by 1.34%. We discuss Pfizer’s buy of Angiosyn, Progenics’ positive Phase II trial, Parexel’s good numbers, Guilford’s mysterious rise, and CytRx’s amazing jump on a recommendation.
